



HAL
open science

Sleep disturbance and impulsive-compulsive behaviours in Parkinson's Disease

Sean S O'Sullivan, Clare M Loane, Andrew D Lawrence, Andrew H Evans,
Paola Piccini, Andrew J Lees

► **To cite this version:**

Sean S O'Sullivan, Clare M Loane, Andrew D Lawrence, Andrew H Evans, Paola Piccini, et al..
Sleep disturbance and impulsive-compulsive behaviours in Parkinson's Disease. *Journal of Neurology,
Neurosurgery and Psychiatry*, 2010, 82 (6), pp.620. 10.1136/jnnp.2009.186874 . hal-00591160

HAL Id: hal-00591160

<https://hal.science/hal-00591160>

Submitted on 7 May 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

O'Sullivan 1

Title Page

Sleep disturbance and impulsive-compulsive behaviours in Parkinson's Disease

Sean S. O'Sullivan, MRCPI ^{1,2}, Clare M. Loane, MSc ², Andrew D. Lawrence, PhD ³,
Andrew H. Evans, MD ⁴, Paola Piccini, PhD ², Andrew J. Lees, FMedAcadSci ¹

¹ Reta Lila Weston Institute of Neurological Studies, University College London, UK.

² Division of Clinical Neurosciences and MRC Clinical Sciences Centre, Faculty of
Medicine, Hammersmith Hospital, Imperial College London, London, UK

³ Wales Institute of Cognitive Neuroscience, School of Psychology, Cardiff
University, UK

⁴ Department of Neurology, Royal Melbourne Hospital, Victoria, Australia

Word count excl abstract, tables, references = 1536

Word count of abstract = 142

Character count for title = 76

Number of references = 23

Number of Figures = 1

Number of tables = 1

Corresponding author:

Professor Andrew J Lees

Reta Lila Weston Institute of Neurological Studies, UCL

1 Wakefield Street,

London, WC1N 1PJ

United Kingdom

O'Sullivan 2

Email address: alees@ion.ucl.ac.uk

Telephone number: Tel: 004420 76794191 Fax number: 004420 7679 4236

Dr Sean S. O'Sullivan and Clare M. Loane completed the statistical analysis

Other authors' emails:

sosulliv@ion.ucl.ac.uk

c.loane@imperial.ac.uk

lawrencead@Cardiff.ac.uk

andrewhevans@yahoo.com

paola.piccini@imperial.ac.uk

There are no supplementary data to this manuscript.

Keywords: Parkinson's disease; Sleep disorders; Bipolar Spectrum Disorders;

Nonmotor symptoms; Impulse control disorders

Disclosure: This work was supported by funding from the Reta Lila Weston Institute and the UK Parkinson's Disease Society. The authors have no financial disclosures to make.

Abstract

Objectives: Impulsive-compulsive behaviours (ICBs) in Parkinson's Disease (PD) have been anecdotally linked with impaired sleep. We investigate measures of sleep in PD patients with and without ICBs, and in healthy controls.

Methods: We compare Parkinsonian features, measures of depression, anxiety and mania, and sleep disturbance in 30 PD patients with ICBs (PD+ICB), 62 PD patients without ICBs (PD - ICB), and 48 healthy controls.

Results: PD+ICB patients had younger age of PD onset, took more dopamine replacement therapy (DRT), had worse sleep, and elevated anxiety, depression and mania scores. Using multiple linear regression analyses, the total anxiety and depression scores, and presence of ICBs were the only variables associated with poorer sleep in PD.

Conclusions: PD+ICB patients may show enhanced psychomotor effects of DRT that may in turn contribute to poor sleep quality. Sleep disturbance should be specifically queried in PD+ICB patients.

Introduction

Although Parkinson's disease (PD) is defined by bradykinesia, rigidity and tremor at rest, a fragmented sleep pattern with insomnia is a common complaint, affecting approximately 66% of patients in one study.[1]

Impulsive-compulsive behaviours (ICBs) are increasingly recognized as a complication of dopamine replacement therapy (DRT), including pathological gambling (PG), hypersexuality (HS), compulsive shopping (CS), binge eating (BE), punding, and the dopamine dysregulation syndrome (DDS) .[2] [3] [4] Although the aetiology of ICBs remains to be clarified, a "global sensitization" of appetitive behaviours has been proposed.[3]

Anecdotal evidence links ICBs, DRT and impaired sleep. For example, DRT induces restlessness, insomnia, nightmares and vivid dreaming, [3] [5] and dopamine is now known to play a prominent role in promoting wakefulness.[6] This study is the first to specifically investigate sleep disturbances in PD patients with ICBs and tests the hypothesis that higher levels of DRT, ICB diagnosis and/or mood, are related to sleep disturbance.

Methods

Outpatients attending a specialist PD clinic were assessed by the lead author for the presence of ICBs in a semi-structured interview using proposed criteria.[3] [2] [4] REM sleep behaviour disorder (RBD) was identified during the clinical interview, according to International Classification of Sleep Disorders criteria.[7] Patients were screened using the Mini-Mental State Examination (MMSE) and 15 who scored

below 26 were excluded because of the requirement to complete self-report scales.

The Unified PD Rating Scale (UPDRS) part 3 was rated in the “on” state by the treating physician. Calculation of a daily L-dopa equivalent dose (LED) dose for each patient was based on theoretical equivalence of dopamine agonists to L-dopa.[4]

Healthy controls without PD or dementia were identified from partners or friends of participating patients attending the outpatient department.

Questionnaires. Participants who provided written informed consent to protocols approved by the UCLH Trust local ethics committee were given a series of questionnaires to complete in their own time and return in a reply-paid envelope. These included the PD Sleep Scale (PDSS),[8] the Mood Disorder Questionnaire (MDQ),[9] and The Hospital Anxiety and Depression Scale (HADS).[10]. The MDQ is a patient-completed bipolar disorder screen, with 73% sensitivity and 90% specificity in the identification of bipolar spectrum disorders.[9]

Data analysis. Data were analyzed with SPSS 14, SPSS Inc., Chicago, IL. Medians/means were compared using Kruskal-Wallis, Mann-Whitney *U* tests (MWU), one-way analyses of variance (ANOVA), or Student *t* test where appropriate. Post-hoc multiple comparisons within a variable using ANOVA were corrected by the Bonferroni method. Kolmogorov-Smirnov tests showed that PDSS and MDQ scores were not normally distributed. Levene's test showed that all variables tested exhibited homogeneity of variance. Univariate correlations between PDSS score and variables such as total anxiety score of HADS, total depression score of HADS, total score of the MDQ symptoms, daily L-dopa amounts used, and daily LED of dopamine

agonists used were made using Spearman's or Pearson's correlation as appropriate.

Factors were entered in a multiple linear regression model to identify clinical features that were independently associated with total PDSS scores. Backward entry method was used, with the probability for stepwise removal set at 0.1. To check the consistency of the model a forward approach with a probability of stepwise entry of 0.05 was also used. Variables entered in the statistical model with total PDSS score as the dependent variable included age, gender, combined total anxiety + depression score of HADS (due to significant univariate correlation between the two HADS subscales, these results were not entered separately), total score of the MDQ symptoms, daily L-dopa amounts used, daily LED of dopamine agonists used, and the presence of documented ICBs.

Results

Participant demographics and PD history

One hundred and thirty three patients with PD received questionnaires, and 41 either did not consent or did not return the questionnaires. Thirty patients who completed the questionnaires were identified as ICBs (PD+ICB), and many of these exhibited more than one ICB. These included 15 with punding, 12 with hypersexuality, 11 with pathological gambling, 8 with compulsive shopping and 8 with binge eating. Forty eight healthy controls were also included. (Table 1). Antidepressant and/or anxiolytic

O'Sullivan 7

were used in 28.6% of PD+ICB (28.6%), and 16.1% of PD-ICB patients, (Chi-square = 1.2, df = 1, p=0.28).

Table 1. Participant details, sleep and mood results

	PD total group	PD + ICB	PD – ICB	Healthy controls	Statistic (P value)
N	92	30	62	48	
M:F	70:22	24:6	46:16	39:9	$\chi^2=0.88$, df = 2, (p=0.6)
Age	64.4 ± 9.9	58.9 ± 8.5* ‡	66.4 ± 9.7* †	57.9 ± 10.6†‡	ANOVA F (2,134) = 11.6, (p <0.0005) * 0.003 † <0.0005 ‡ = 1.0
Age PD onset.	52.3 ± 12.7	46.2 ± 10.1*	55.8 ± 12.0*	N/A	* t=3.6, df = 66, (p=0.001)
Duration of PD (years)	10.5 ± 6.7	11.5 ± 5.9*	9.5 ± 7.0*	N/A	*t= 1.2, df = 67, (p=0.2)
H + Y on medications Median (interquartile range)	2 (2-3)	3 (2.1-3)*	2 (2-3)*	N/A	* MWU = 67, *(p = 0.04)
Current L-dopa dose/day (mg)	597 ± 443	701 ± 508*	543 ± 399*	N/A	* t=1.4, df = 73, (p = 0.16)
Current DA LEU dose/day (mg) Median (interquartile range)	90, (0-262)	201, (0-284)*	0, (0-201)*	N/A	* MWU = 555, (p=0.12)
Combined L-dopa + DA LEU/day (mg).	764 ± 548	981 ± 651*	645 ± 443*	N/A	*t=-2.5, df = 75, (p=0.018)
RBD diagnosed	19/55 (34.5%)	7/18* (38.9%)	12/37* (32.4%)	Not included	* $\chi^2=0.03$, df = 1, (p=0.9)
HADS anxiety score	15.0 ± 3.6	16.9 ± 3.9‡†	14.3 ± 3.2‡*	13.9 ± 3.9*†	ANOVA F (2,128) = 6.9 (p=0.001) * = 1.0 ‡ = 0.005 † = 0.002
HADS depression score	13.2 ± 3.1	14.5 ± 3.5‡†	12.8 ± 2.7‡*	9.9 ± 2.9*†	ANOVA F (2,129) = 23.7 (p <0.0005) * = <0.0005 ‡ = 0.053 † <0.0005
Mania symptom score Median (interquartile range)	3, (1-7)	6, (3-8) †‡	3, (1-6) *‡	2, (0-5) *†	Kruskal-Wallis Chi Square = 13, df = 2, (p=0.002) * MWU (p=0.6) ‡ MWU (p=0.002) † MWU (p=0.001)

Means are compared with t-tests, except where indicated

All values are mean +/- SD except where indicated

ANOVA = analysis of variance. Post-hoc multiple comparisons within a variable using ANOVA were corrected by the Bonferroni method.

O'Sullivan 9

MWU = Mann Whitney U test

SD = Standard deviation

df = degrees of freedom


Sleep disturbance, mood and ICBs

PD patients had worse sleep scores than healthy controls ($p < 0.0005$), and the PD + ICB group had worse sleep than the PD-ICB ($p = 0.006$). Figure 1. Of the 92 PD patients included, the presence or absence of RBD was elicited in 55 (60%), with the vast majority of the remainder being unclassifiable due to the lack of witnessed sleep behaviours. (Table 1).

No participants had a diagnosis of bipolar mood disorder. 30% of PD + ICB, 3.2% of the PD-ICB, (Chi-square = 13.8, $df = 1$, $p < 0.0005$), and 4.2% of healthy controls scored above the recommended cut-off for bipolar spectrum disorder on the MDQ.[9]

No clinical differences were seen when comparing PD patients with and without RBD.

Figure: PD Sleep Scale total scores



Median scores are compared with Mann Whitney U tests. Lines denote the median values; box denotes specific interquartile range. Maximum and minimum scores are indicated by the upper and lower markers, respectively. Lower scores are associated with worse sleep quality.

Predictors of sleep disturbance in PD

In the combined PD group, there was a negative correlation between sleep impairment (total PDSS score) and anxiety (Pearson Correlation coefficient = -0.39, $p < 0.00005$), and depression (Pearson Correlation coefficient = -0.34, $p = 0.001$). No correlations were seen between PDSS totals and variables such as age, gender, or DRT amounts.

In all univariate analyses, the non-significant correlation coefficients were all $< |0.22|$

Using multiple linear regression analyses, the presence of ICBs ($p = 0.045$) and combined HADS anxiety + depression totals ($p = 0.068$) were the only variables associated with sleep disturbance in PD ($p = 0.004$).

Discussion

PD patients with ICBs have poorer sleep quality, compared to PD patients without ICBs and healthy controls. Several clinical differences were found between the PD + ICB and PD-ICB groups including age and medication use but are unlikely to account for the observed poor sleep quality. PD + ICB patients were on average 8 years younger at time of study despite a similar PD duration in both groups. The exclusion of patients scoring < 26 on the MMSE might disproportionately exclude older patients,

those with a longer history or those in who decisions to reduce DRT have been made because of cognitive or psychotic problems. Previous studies have found that age does not correlate with PDSS scores,[11] but normal aging is accompanied by decreased ability to initiate and maintain sleep, and a decrease in the proportion of the more restorative slow-wave sleep and rapid eye movement sleep.[12] Age differences alone therefore, cannot explain why the PD+ICB group have a poorer quality of sleep than PD-ICB patients.

PD+ICB patients had higher rates of mood disturbance, which could potentially directly impact sleep quality. In PD, the association between sleep disturbances and mood disorders is well established.[13] [14] PD patients had increased anxiety and depression than controls, with PD+ICB more so than PD-ICB. Consistent with previous reports,[14] we found a correlation between poor sleep scores and depression and anxiety severity.

The PD + ICB patients had higher MDQ scores than the PD-ICB patients; although the MDQ has not been validated for use in PD. None of the included PD participants fulfilled diagnostic criteria for bipolar mood disorder. However, in our study 29% of PD + ICB, 3.2% of the PD – ICB group, and 4.2% of healthy controls scored above the recommended cut-off for bipolar spectrum disorder.[9] A recent large study of bipolar disorders including sub-threshold bipolar disorder found a lifetime prevalence of 4.4% amongst the general population.[15] The increased frequency of manic

symptoms in the PD patients may relate to medication-effects which have been recognised since the introduction of L-dopa.[16] An association between medication-induced hypomania and pathological gambling in PD has been described,[2] in contrast with patients developing ICBs after being treated with dopaminergic medications for restless legs syndrome, where none describe medication-induced mania.[17] As with any work involving multiple comparisons, caution is required regarding the risk of false positive results.

Although the PD+ICB group were using more DRT than the PD-ICB patients, notably neither the daily amount of L-dopa nor dopamine agonist medication use correlated with altered sleep scores or RBD frequency. These results suggest that it is not simply the amount of DRT that causes poor sleep quality. This finding differs from previous reviews which have suggested an association between DRT and nightmares,[18] and RBD[19]

The presence of ICBs was identified as being independently associated with sleep disturbance. This suggests that PD+ICB patients may be more sensitive to the psychomotor stimulant-arousal effects of DRT, which in turn contributes to poorer sleep. Punding behaviours, may contribute to poor sleep quality as a consequence of persistence of these stereotyped behaviours throughout the night at the expense of a normal sleep pattern.[4] However, we found no difference when comparing sleep scores in PD+ICB patients with or without punding ($p = 0.7$, MWU) This is consistent with animal models, showing an effect of dopamine on wakefulness independent of

motor stereotypies.[20] Alternatively, sleep disturbance in PD + ICB might relate to underlying impulsive personality traits, which are risk factors for developing ICBs,[21] and which are linked with insomnia independent of DRT use.[22] Sleep disruption has also been suggested to heighten psychomotor sensitization effects,[23] which could impact on the expression of ICDs in PD. Further work is needed in this area, and we conclude that sleep disturbance should be specifically queried in PD+ICB patients.

Acknowledgements: This work was supported by funding from the Reta Lila Weston Institute and the UK Parkinson's Disease Society. The study sponsors had no role in study design; in the collection, analysis, and interpretation of data; or in the writing of the report. The authors are grateful for the help received from participants in this study. Dr Constantinos Kallis provided statistical advice. The authors have no financial disclosures to make.

Statement:

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in JNNP and any other BMJ PGL products to exploit all subsidiary rights, as set out in our licence (<http://jnnp.bmjournals.com/ifora/licence.pdf>).

References:

1. Tandberg E, Larsen JP, Karlsen K: A community-based study of sleep disorders in patients with Parkinson's disease. *Mov Disord* 1998, **13**:895-899.
2. Voon V, Fox SH: Medication-related impulse control and repetitive behaviors in Parkinson disease. *Arch Neurol* 2007, **64**:1089-1096.
3. Lawrence AD, Evans AH, Lees AJ: Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? *Lancet Neurol* 2003, **2**:595-604.
4. Evans AH, Katzenschlager R, Paviour D, O'Sullivan JD, Appel S, Lawrence AD, Lees AJ: Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. *Mov Disord* 2004, **19**:397-405.
5. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL: Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. *Clin Neuropharmacol* 1982, **5**:183-194.
6. Boutrel B, Koob GF: What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. *Sleep* 2004, **27**:1181-1194.
7. American Sleep Disorders Association: International classification of sleep disorders, revised: diagnostic and coding manual. pp. 177-180. Rochester, MN: American Sleep Disorders Association; 1997:177-180.
8. Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, Pezzela FR, Forbes A, Hogl B, Trenkwalder C: The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2002, **73**:629-635.
9. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE, Jr., Lewis L,

- McElroy SL, Post RM, Rappport DJ, et al: Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. *Am J Psychiatry* 2000, **157**:1873-1875.
10. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983, **67**:361-370.
 11. Gomez-Esteban JC, Zarranz JJ, Lezcano E, Velasco F, Ciordia R, Rouco I, Losada J, Bilbao I: Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease. *Mov Disord* 2006, **21**:983-988.
 12. Espiritu JR: Aging-related sleep changes. *Clin Geriatr Med* 2008, **24**:1-14, v.
 13. Martinez-Martin P, Visser M, Rodriguez-Blazquez C, Marinus J, Chaudhuri KR, van Hilten JJ: SCOPA-sleep and PDSS: two scales for assessment of sleep disorder in Parkinson's disease. *Mov Disord* 2008, **23**:1681-1688.
 14. Borek LL, Kohn R, Friedman JH: Mood and sleep in Parkinson's disease. *J Clin Psychiatry* 2006, **67**:958-963.
 15. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. *Arch Gen Psychiatry* 2007, **64**:543-552.
 16. Ryback RS, Schwab RS: Manic response to levodopa therapy. Report of a case. *N Engl J Med* 1971, **285**:788-789.
 17. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, Krahn L, Adler CH: Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. *Clin Neuropharmacol* 2007, **30**:249-255.
 18. Pagel JF, Helfter P: Drug induced nightmares--an etiology based review. *Hum Psychopharmacol* 2003, **18**:59-67.
 19. Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP: Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson's disease over time. *J Neurol Neurosurg Psychiatry* 2008, **79**:387-391.
 20. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM: Dopaminergic role in stimulant-induced wakefulness. *J Neurosci* 2001, **21**:1787-1794.
 21. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ: Factors influencing susceptibility to

- compulsive dopaminergic drug use in Parkinson disease. *Neurology* 2005, **65**:1570-1574.
22. Schmidt RE, Gay P, Van der Linden M: Facets of impulsivity are differentially linked to insomnia: evidence from an exploratory study. *Behav Sleep Med* 2008, **6**:178-192.
23. Frussa-Filho R, Goncalves MT, Andersen ML, de Araujo NP, Chinen CC, Tufik S: Paradoxical sleep deprivation potentiates amphetamine-induced behavioural sensitization by increasing its conditioned component. *Brain Res* 2004, **1003**:188-193.

